Addressing diversity barriers in prostate cancer clinical trials for equitable healthcare outcomes

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology Pub Date : 2025-02-18 DOI:10.1038/s41585-025-01008-8

Peter Lang, Matt Vassar

引用次数: 0

Abstract

Prostate cancer is the most common cancer in men, yet disparities persist in screening, diagnosis and treatment among populations with low socioeconomic status. Minority groups face barriers to clinical trial inclusion including limited awareness and financial challenges. Promoting diversity in clinical trials is crucial for inclusivity, improving treatment efficacy and achieving equitable health outcomes in prostate cancer care.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Urology 医学-泌尿学与肾脏学

CiteScore

12.50

自引率

2.60%

发文量

123

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.